A Phase 1b/2 Study of AVB-S6-500 in Combination with Cabozantinib, AVB-S6-500 in Combination with Cabozantinib and Nivolumab, and AVB-S6-500 Monotherapy in Patients with Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Protocol No
ARAVIVE-AVB500-RCC-003
Principal Investigator
Ariel Nelson
Phase
I/II
Summary
The purpose of this research study is to evaluate the safety and effectiveness of AVB-S6-500 combined with Cabozantinib, or the combination of Cabozantinib and Nivolumab, or AVB-S6- 500 monotherapy (AVB-S6-500 given alone), are in patients with advanced or metastatic clear cell renal cell carcinoma.
Description
Safety and Efficacy Study of AVB-S6-500 in Patients With Advanced Clear Cell Renal Cell Carcinoma
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL